Allogene Therapeutics (ALLO) SVP sells shares in tax-related sell-to-cover

Rhea-AI Filing Summary

Allogene Therapeutics SVP and Chief Technical Officer Benjamin Machinas Beneski reported a small sale of 2,867 shares of Common Stock at $2.50 per share. The company states this transaction was executed solely to cover tax withholding obligations tied to vesting restricted stock units under its equity incentive plan.

Following the sale, Beneski directly holds 195,338 shares of Allogene Therapeutics common stock. The filing explains the sale was a mandatory “sell to cover” transaction chosen by the company’s plan and is not a discretionary trade by the executive.

Insights

Equity compensation analyst

Mandatory tax-related sale with minimal signaling impact.

The transaction covers 2,867 Allogene Therapeutics shares sold at $2.50 per share to fund tax withholding on vesting restricted stock units. The company’s equity plan requires a “sell to cover” approach, so the executive did not choose the timing or amount as an open-market trade.

After the sale, Benjamin Machinas Beneski still directly owns 195,338 shares, indicating this is a small, mechanical adjustment relative to his position. Because the sale is mandated for tax purposes rather than discretionary, it carries limited information about his view of the stock.

Insider Trade Summary

Net Seller: 2,867 shares ($7,168)

Net Sell 1 txn

Insider Beneski Benjamin Machinas

Role SVP, Chief Technical Officer

Sold 2,867 shs ($7K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,867	$2.50	$7K

Holdings After Transaction: Common Stock — 195,338 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 2,867 shares Sale price: $2.50 per share Shares owned after sale: 195,338 shares

3 metrics

Shares sold 2,867 shares Open-market tax-related sale on 2026-03-31

Sale price $2.50 per share Price for shares sold to cover tax withholding

Shares owned after sale 195,338 shares Direct holdings following the reported transaction

Key Terms

restricted stock units, tax withholding obligations, equity incentive plan, sell to cover

4 terms

restricted stock units financial

"in connection with the vesting of restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"sold by the reporting person to cover tax withholding obligations in connection"

equity incentive plan financial

"mandated by the Issuer's election under its equity incentive plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

sell to cover financial

"funded by a "sell to cover" transaction and does not represent"

Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Beneski Benjamin Machinas

(Last) (First) (Middle)

210 EAST GRAND AVENUE

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Allogene Therapeutics, Inc. [ ALLO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Technical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/31/2026		S		2,867(1)	D	$2.5	195,338	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

Remarks:

	/s/Earl Douglas, Attorney-in-Fact	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Allogene Therapeutics (ALLO) report for Benjamin Machinas Beneski?

Allogene Therapeutics reported that SVP and Chief Technical Officer Benjamin Machinas Beneski sold 2,867 shares of common stock at $2.50 per share. The sale was linked to restricted stock unit vesting and associated tax obligations under the company’s equity incentive plan.

Why did Allogene Therapeutics (ALLO) executive Beneski sell 2,867 shares?

The 2,867-share sale was executed to cover tax withholding obligations arising from the vesting of restricted stock units. Allogene’s equity incentive plan mandates a “sell to cover” method for taxes, so this transaction reflects a required tax event rather than a discretionary stock sale.

Was Beneski’s Allogene Therapeutics (ALLO) share sale a discretionary trade?

No, the filing states the sale does not represent a discretionary trade by Benjamin Machinas Beneski. It was mandated by the company’s equity incentive plan as a “sell to cover” transaction to fund tax withholding when his restricted stock units vested.

How many Allogene Therapeutics (ALLO) shares does Beneski own after this Form 4?

After selling 2,867 shares to cover taxes, Benjamin Machinas Beneski directly holds 195,338 shares of Allogene Therapeutics common stock. This indicates the reported transaction is small relative to his overall position and primarily administrative in nature.

What price was received for the Allogene Therapeutics (ALLO) shares sold by Beneski?

The reported sale price was $2.50 per Allogene Therapeutics common share. This price applied to the 2,867 shares sold to satisfy tax withholding obligations associated with vesting restricted stock units under the company’s equity incentive plan.